“The United States should have the best medical
Post# of 157825
Awesome thank you for providing this! For everyone else. You aren’t wrong but I’ll leave you with this. Let’s keep the discussion focused on the actual impact of NIH funding on the company. Fear mongering and misinformation especially from sources like the WSJ, which isn’t exactly known for accuracy aren’t helpful. It’s fine to debate how this might affect the company, but keep it on track. If the conversation veers off, posts will be removed.
People keep panicking over different things every few days, and more often than not, the situation changes before anything even happens. Let's stick to what actually matters to the company when it comes to the NIH. This could be negative for sure, but we have yet to really know the impact, if any at all. A lot of our grants are already funded.
The news has everyone hooked. Turn it off for a little.
CytoDyn Inc (CYDY) Stock Research Links
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36